New Conning Study – 91% of insurance executives believe climate risk a threat
HARTFORD, Conn., Oct. 18, 2024 /PRNewswire/ — The issue of assessing and managing climate change risk, both physical and transitional, has become increasingly... Read more.
New Conning Study – 91% of insurance executives believe climate risk a threat
HARTFORD, Conn., Oct. 18, 2024 /PRNewswire/ — The issue of assessing and managing climate change risk, both physical and transitional, has become increasingly... Read more.
CoreWeave Announces Appointment of Michelle O’Rourke as Chief People Officer
O’Rourke to oversee the company’s human resources department and will now serve on the company’s executive leadership team. ROSELAND, N.J., Oct.... Read more.
CoreWeave Announces Appointment of Michelle O’Rourke as Chief People Officer
O’Rourke to oversee the company’s human resources department and will now serve on the company’s executive leadership team. ROSELAND, N.J., Oct.... Read more.
LeasePoint Secures $40 Million Incremental Funding
AUSTIN, TX, Oct. 18, 2024 /PRNewswire/ — LeasePoint Funding Group, LLC (“LeasePoint” or the “Company”) today announced that it has... Read more.
LeasePoint Secures $40 Million Incremental Funding
AUSTIN, TX, Oct. 18, 2024 /PRNewswire/ — LeasePoint Funding Group, LLC (“LeasePoint” or the “Company”) today announced that it has... Read more.
Vida Integrates OpenAI’s New Realtime Speech-to-Speech API, Staying Ahead of the Voice AI Revolution
One Of The First Platforms To Integrate, Vida’s AI Phone Agents Now Deliver Emotionally Expressive, Multilingual Conversations, Setting A New Benchmark In... Read more.
Vida Integrates OpenAI’s New Realtime Speech-to-Speech API, Staying Ahead of the Voice AI Revolution
One Of The First Platforms To Integrate, Vida’s AI Phone Agents Now Deliver Emotionally Expressive, Multilingual Conversations, Setting A New Benchmark In... Read more.
Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease
DUBLIN, Oct. 18, 2024 /PRNewswire/ — Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today announced... Read more.
Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease
DUBLIN, Oct. 18, 2024 /PRNewswire/ — Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today announced... Read more.